|
시장보고서
상품코드
2039048
성 건강 시장 : 제품 유형별, 성별, 유통 채널별, 지역별Sexual Health Market, By Product Type, By Gender, By Distribution Channel, By Geography |
||||||
성 건강 시장은 2026년에 456억 7,000만 달러로 추정되며, 2033년까지 829억 4,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR은 8.9%를 보일 전망입니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 456억 7,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR | 8.90% | 예측 금액(2033년) | 829억 4,000만 달러 |
성 건강은 사람의 심신 건강에 있어 중요한 요소입니다. 성 건강은 성기능 장애가 없는 건강한 성생활로 이어지며, 성병을 예방하기 위한 조치로 이어집니다. 성인 인구의 상당수는 성교통, 발기부전, 발기부전, 성욕감퇴증, 조루증 등 한 가지 이상의 성기능 장애를 겪고 있습니다. 미국 국립생물공학정보센터(NCBI)의 2016년 보고서에 따르면, 성기능 장애는 전 세계적으로 여성의 약 43%, 남성의 약 31%가 겪고 있는 매우 높은 유병률을 보이고 있습니다. 현재 이러한 성기능 장애를 치료하고 개인의 성건강을 향상시키기 위해 약물 치료, 기계적 보조기구, 성치료 등 다양한 치료법이 이용되고 있습니다.
시장 역학
성기능 장애의 발생률과 유병률 증가는 시장 성장을 가속하는 주요 요인입니다. 성기능 장애를 유발하는 주요 요인으로는 노화, 스트레스와 불건강한 생활습관, 기타 심리적 요인 등을 들 수 있습니다. 2016년 4월 미국 국립생물공학정보센터(NCBI)에서 발표한 연구에 따르면, 18-44세 여성의 약 8.9%, 45-64세 여성의 약 12.3%가 성욕감퇴장애(HSDD)를 앓고 있습니다.
또한, 성 건강을 개선하기 위한 혁신적이고 매우 효과적인 치료법을 도입하기 위해 주요 주요 기업들의 활발한 제품 개발 활동이 진행되고 있습니다. 예를 들어, 2019년 6월 AMAG 파마슈티컬스는 폐경 전 여성의 후천성 및 전반적 성욕감퇴증(HSDD) 치료제로 Vyleesi(브레멜라노타이드)에 대한 미국 식품의약국(FDA)의 승인을 받았습니다. 따라서 규제 당국의 승인 증가가 성 건강 시장의 성장을 견인할 것으로 예측됩니다.
본 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 성 건강 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등 다양한 파라미터를 기준으로 정리하여 수록하였습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 성 건강 시장' 보고서는 투자자, 기술 제조업체, 유통업체, 성 건강 제품 공급업체, 연구 및 컨설팅 회사, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 성 건강 시장 : 제품 유형별(2021년-2033년)
제5장 세계의 성 건강 시장 : 성별(2021년-2033년)
제6장 세계의 성 건강 시장 : 유통 채널별(2021년-2033년)
제7장 세계의 성 건강 시장 : 지역별(2021년-2033년)
제8장 경쟁 구도
제9장 섹션
LSH 26.06.04Sexual Health Market is estimated to be valued at USD 45.67 Bn in 2026 and is expected to reach USD 82.94 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 45.67 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.90% | 2033 Value Projection: | USD 82.94 Bn |
Sexual health is an important part of a person's physical and mental health. Sexual health leads to the healthy sexual life without any sexual dysfunctions, and preventive measures to avoid sexually transmitted infections. The adult population largely suffers from one or more sexual disorders such as dyspareunia, erectile dysfunctions, hypoactive sexual desire disorder, premature (early) ejaculation, and others. According to National Center for Biotechnology Information 2016, sexual dysfunction is highly prevalent, and affects around 43% of women and 31% of men, globally. Currently, various treatment options such as medication, mechanical aids, sexual therapies, and others are available for treating such sexual dysfunctions and to improve sexual health of the person.
Market Dynamics
Increasing incidence and prevalence of sexual disorders is a major factor augmenting growth of the market. Some of the major factors which cause sexual dysfunction are aging population, stressful and unhealthy lifestyle, and other psychological parameters. According to a study published in the National Center for Biotechnology Information in April 2016, hypoactive sexual desire disorder (HSDD) is present in around 8.9% and 12.3% women in the age group of 18 - 44 years and 45 - 64 years, respectively.
Moreover, robust product development activities by major key players is engaged in the introduction of innovative and highly effective drug treatment for improving sexual health. For instance, in June 2019, AMAG Pharmaceuticals received the U.S. FDA approval for Vyleesi (bremelanotide) for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Thus, increasing approvals by regulatory authorities are expected to drive the growth of the sexual health market.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new technology launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles leading players in the global sexual health market based on the following parameters - company overview, financial performance, technology portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future technology launches, government initiatives, technological upgradation, market expansion, and marketing tactics
- The global sexual health market report caters to various stakeholders in this market, including investors, technology manufacturers, distributors, and suppliers in the sexual health market, research and consulting firms, new entrants, and financial analysts
Market Segmentation
- Global Sexual Health Market, By Product Type
- Erectile Dysfunction Drugs
- Gender Dysphoria Drugs
- Hypoactive Sexual Desire Disorder Drugs
- Premature Ejaculation Drugs
- Others
- Global Sexual Health Market, By Gender
- Male
- Female
- Global Sexual Health Market, By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Sexual Health Market, By Region
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players
- Eli Lilly and Company
- Viatris
- Bayer AG
- Organon & Co.
- Gilead Sciences
- ViiV Healthcare
- Perrigo Company plc
- Reckitt
- Church & Dwight Co., Inc.
- CooperSurgical
- LifeStyles Healthcare
- Karex Berhad
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Gender
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Technology Advancements
- Merger and Acquisition
- Regulatory Scenario
- PORTER'S Five Forces
- PEST Analysis
4. Global Sexual Health Market, By Product Type, 2021- 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Erectile Dysfunction Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Gender Dysphoria Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hypoactive Sexual Desire Disorder Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Premature Ejaculation Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Sexual Health Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Sexual Health Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Sexual Health Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022 - 2033
- Regional Trends
- North America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Meda Pharmaceuticals, Inc.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Eli Lilly & Company
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Bayer AG
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Vivus, Inc.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Zydus Pharmaceuticals
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- IVFTECH APS
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Merck & Co.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Mylan Pharmaceuticals Inc.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- AstraZeneca
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Teva Pharmaceutical Industries Ltd.
9. Section
- References
- Research Methodology
- About us and Sales Contact
